Did you know? In generalized myasthenia gravis, pathogenic IgG autoantibodies — primarily anti-AChR — disrupt neuromuscular transmission. An FcRn antagonist that reduces total IgG levels offers a targeted mechanism independent of broad immunosuppression. In the Phase 3 ADAPT trial (n=167), 67.7% of AChR antibody-positive patients achieved a clinically meaningful MG-ADL response vs. 29.7% with placebo (p<0.0001), with rapid onset of benefit observed within the first two weeks of a treatment cycle.
From a managed care perspective, how does an FcRn-based approach that enables individualized, on-demand dosing cycles change the cost-effectiveness conversation for gMG compared with fixed-schedule immunosuppressants?
From a managed care perspective, how does an FcRn-based approach that enables individualized, on-demand dosing cycles change the cost-effectiveness conversation for gMG compared with fixed-schedule immunosuppressants?
-
Amber Cook3dPotentially allows patients to achieve disease burden with need for less immunosuppressive therapies, which can ultimately reduce costs, and hopefully would reduce side effects and secondary infections that could also drive costs due to need for additional care access to address those secondary effects.
-
Temeki Hill5dit all comes down to insurance and coverage options
-
SHABNAM SACHDEVA2wCost of FcRn antagonists and prior authorization hurdles make them inaccessible option for some patients even though they are effective and rapidly acting
-
SACHINKUMAR PANCHAL2wOverall, the idea is that using treatment only when it’s needed may improve outcomes while potentially reducing some other healthcare costs, but the total value depends on each patient’s situation and the therapy’s overall cost.